Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 73799 | 4.325 |
09:34 ET | 60814 | 4.325 |
09:36 ET | 23813 | 4.315 |
09:38 ET | 15781 | 4.355 |
09:39 ET | 18950 | 4.355 |
09:41 ET | 10651 | 4.355 |
09:43 ET | 41052 | 4.4051 |
09:45 ET | 97092 | 4.42 |
09:48 ET | 75107 | 4.435 |
09:50 ET | 48461 | 4.44 |
09:52 ET | 39056 | 4.445 |
09:54 ET | 15722 | 4.45 |
09:56 ET | 62906 | 4.455 |
09:57 ET | 25479 | 4.455 |
09:59 ET | 146799 | 4.465 |
10:01 ET | 29315 | 4.47 |
10:03 ET | 28511 | 4.465 |
10:06 ET | 10683 | 4.4601 |
10:08 ET | 70301 | 4.485 |
10:10 ET | 111614 | 4.495 |
10:12 ET | 56524 | 4.5 |
10:14 ET | 95089 | 4.495 |
10:15 ET | 112337 | 4.465 |
10:17 ET | 151298 | 4.46 |
10:19 ET | 83230 | 4.455 |
10:21 ET | 31599 | 4.4501 |
10:24 ET | 223296 | 4.455 |
10:26 ET | 36026 | 4.455 |
10:28 ET | 17040 | 4.455 |
10:30 ET | 41502 | 4.455 |
10:32 ET | 22250 | 4.454 |
10:33 ET | 144552 | 4.4514 |
10:35 ET | 66602 | 4.43 |
10:37 ET | 26192 | 4.43 |
10:39 ET | 9001 | 4.435 |
10:42 ET | 6850 | 4.435 |
10:44 ET | 14527 | 4.436 |
10:46 ET | 48565 | 4.435 |
10:48 ET | 22577 | 4.435 |
10:50 ET | 2086 | 4.43 |
10:51 ET | 1000 | 4.43 |
10:53 ET | 7902 | 4.435 |
10:55 ET | 6113 | 4.435 |
10:57 ET | 5689 | 4.435 |
11:00 ET | 2700 | 4.435 |
11:02 ET | 13175 | 4.43 |
11:04 ET | 39742 | 4.4108 |
11:06 ET | 33577 | 4.41 |
11:08 ET | 14171 | 4.41 |
11:09 ET | 10387 | 4.42 |
11:11 ET | 7057 | 4.41 |
11:13 ET | 3800 | 4.41 |
11:15 ET | 2884 | 4.41 |
11:18 ET | 3276 | 4.415 |
11:20 ET | 407482 | 4.425 |
11:22 ET | 163939 | 4.445 |
11:24 ET | 58952 | 4.445 |
11:26 ET | 9500 | 4.45 |
11:27 ET | 36825 | 4.45 |
11:29 ET | 10351 | 4.445 |
11:31 ET | 38075 | 4.455 |
11:33 ET | 58309 | 4.48 |
11:36 ET | 5209 | 4.48 |
11:38 ET | 15001 | 4.475 |
11:40 ET | 9776 | 4.48 |
11:42 ET | 4154 | 4.475 |
11:44 ET | 164706 | 4.475 |
11:45 ET | 8343 | 4.48 |
11:47 ET | 3245 | 4.475 |
11:49 ET | 4713 | 4.475 |
11:51 ET | 4959 | 4.475 |
11:54 ET | 62492 | 4.49 |
11:56 ET | 4708 | 4.485 |
11:58 ET | 26416 | 4.485 |
12:00 ET | 8471 | 4.485 |
12:02 ET | 27931 | 4.4705 |
12:03 ET | 7076 | 4.46 |
12:05 ET | 4114 | 4.465 |
12:07 ET | 4232 | 4.465 |
12:09 ET | 4242 | 4.46 |
12:12 ET | 6763 | 4.46 |
12:14 ET | 21361 | 4.46 |
12:16 ET | 1100 | 4.465 |
12:18 ET | 2072 | 4.465 |
12:20 ET | 2551 | 4.465 |
12:21 ET | 20262 | 4.465 |
12:23 ET | 15201 | 4.465 |
12:25 ET | 18391 | 4.46 |
12:27 ET | 9611 | 4.465 |
12:30 ET | 1337 | 4.465 |
12:32 ET | 8026 | 4.465 |
12:34 ET | 499 | 4.465 |
12:36 ET | 2410 | 4.465 |
12:38 ET | 8259 | 4.465 |
12:39 ET | 3991 | 4.465 |
12:41 ET | 1351 | 4.465 |
12:43 ET | 12369 | 4.465 |
12:45 ET | 2006 | 4.465 |
12:48 ET | 14805 | 4.465 |
12:50 ET | 6859 | 4.465 |
12:52 ET | 3794 | 4.4632 |
12:54 ET | 756 | 4.465 |
12:56 ET | 1232 | 4.46 |
12:57 ET | 300 | 4.465 |
12:59 ET | 827 | 4.465 |
01:01 ET | 721 | 4.465 |
01:03 ET | 300 | 4.465 |
01:06 ET | 7457 | 4.4601 |
01:08 ET | 2814 | 4.465 |
01:10 ET | 2000 | 4.465 |
01:12 ET | 70710 | 4.4622 |
01:14 ET | 7343 | 4.465 |
01:15 ET | 9002 | 4.465 |
01:17 ET | 2298 | 4.46 |
01:19 ET | 13347 | 4.465 |
01:21 ET | 19876 | 4.455 |
01:24 ET | 11507 | 4.455 |
01:26 ET | 11936 | 4.455 |
01:28 ET | 17123 | 4.455 |
01:30 ET | 76781 | 4.455 |
01:32 ET | 7388 | 4.455 |
01:33 ET | 110815 | 4.455 |
01:35 ET | 22305 | 4.455 |
01:37 ET | 2349 | 4.455 |
01:39 ET | 2200 | 4.455 |
01:42 ET | 12630 | 4.455 |
01:44 ET | 30741 | 4.46 |
01:46 ET | 3832 | 4.465 |
01:48 ET | 4051 | 4.465 |
01:50 ET | 70564 | 4.49 |
01:51 ET | 2501 | 4.489 |
01:53 ET | 65974 | 4.465 |
01:55 ET | 3429 | 4.465 |
01:57 ET | 6283 | 4.465 |
02:00 ET | 1002 | 4.465 |
02:02 ET | 4960 | 4.47 |
02:04 ET | 7085 | 4.465 |
02:06 ET | 3325 | 4.465 |
02:08 ET | 63373 | 4.465 |
02:09 ET | 6508 | 4.46 |
02:11 ET | 17120 | 4.465 |
02:13 ET | 4878 | 4.465 |
02:15 ET | 2743 | 4.465 |
02:18 ET | 1900 | 4.465 |
02:20 ET | 3000 | 4.465 |
02:22 ET | 8132 | 4.465 |
02:24 ET | 79282 | 4.47 |
02:26 ET | 13780 | 4.47 |
02:27 ET | 3100 | 4.465 |
02:29 ET | 122739 | 4.475 |
02:31 ET | 452139 | 4.505 |
02:33 ET | 34042 | 4.515 |
02:36 ET | 15458 | 4.515 |
02:38 ET | 64041 | 4.545 |
02:40 ET | 6795 | 4.545 |
02:42 ET | 7856 | 4.545 |
02:44 ET | 30063 | 4.545 |
02:45 ET | 4333 | 4.545 |
02:47 ET | 100292 | 4.5207 |
02:49 ET | 27112 | 4.51 |
02:51 ET | 73193 | 4.49 |
02:54 ET | 17853 | 4.495 |
02:56 ET | 25241 | 4.495 |
02:58 ET | 1500 | 4.49 |
03:00 ET | 8841 | 4.486 |
03:02 ET | 8199 | 4.49 |
03:03 ET | 45373 | 4.495 |
03:05 ET | 5409 | 4.495 |
03:07 ET | 2400 | 4.495 |
03:09 ET | 4353 | 4.5 |
03:12 ET | 2602 | 4.5 |
03:14 ET | 6198 | 4.495 |
03:16 ET | 3100 | 4.495 |
03:18 ET | 4981 | 4.495 |
03:20 ET | 169529 | 4.515 |
03:21 ET | 2029 | 4.515 |
03:23 ET | 5428 | 4.52 |
03:25 ET | 37454 | 4.515 |
03:27 ET | 8800 | 4.515 |
03:30 ET | 9814 | 4.515 |
03:32 ET | 236831 | 4.535 |
03:34 ET | 5281 | 4.535 |
03:36 ET | 82858 | 4.54 |
03:38 ET | 6673 | 4.54 |
03:39 ET | 69919 | 4.535 |
03:41 ET | 14042 | 4.535 |
03:43 ET | 25267 | 4.54 |
03:45 ET | 12705 | 4.535 |
03:48 ET | 24810 | 4.535 |
03:50 ET | 16924 | 4.54 |
03:52 ET | 42192 | 4.54 |
03:54 ET | 34504 | 4.54 |
03:56 ET | 67696 | 4.535 |
03:57 ET | 290733 | 4.535 |
03:59 ET | 1392071 | 4.6 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.8B | -12.8x | --- |
Iovance Biotherapeutics Inc | 2.8B | -5.6x | --- |
Celldex Therapeutics Inc | 2.7B | -14.9x | --- |
Xenon Pharmaceuticals Inc | 2.9B | -14.2x | --- |
Vera Therapeutics Inc | 2.6B | -21.2x | --- |
Structure Therapeutics Inc | 2.5B | -19.7x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.8B |
---|---|
Revenue (TTM) | $1.4M |
Shares Outstanding | 602.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.50 |
EPS | $-0.36 |
Book Value | $0.46 |
P/E Ratio | -12.8x |
Price/Sales (TTM) | 2,019.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -16,559.94% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.